API
< Back to all clusters
[BUSINESS] · United States, India · 2 sources

started · updated

US generic drug tariffs likely to spare Indian pharma in short term

The United States announced a phased tariff plan for imported generic medicines, keeping tariffs at zero percent until August 1 2026 and then raising them to 100 % for one year and up to 200 % thereafter. Analysts from Infomerics Ratings say the transition period gives Indian pharmaceutical companies ample time to adjust, limiting any immediate impact on their credit profiles. India currently supplies about 30 % of U.S. pharma exports and roughly 40 % of the generic drugs used in Medicare and Medicaid, so the higher tariffs could increase U.S. healthcare costs. Companies with significant U.S. exposure, such as Sun Pharma, Dr Reddy’s, Aurobindo, Zydus and Lupin, may feel more pressure as they derive 35‑50 % of revenues from the U.S. market.

USISPF President Mukesh Aghi warned that a 100 % or 200 % tariff would “basically the cost will go up for the government itself,” highlighting the potential rise in public healthcare spending despite the policy’s aim to bring generic production back to the United States.